| Mrs Susan Audrey Parker, DPT | |
|
51 Sockanosset Cross Rd, Cranston, RI 02920-5536 | |
| (401) 944-7574 | |
| (401) 944-7602 |
| Full Name | Mrs Susan Audrey Parker |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 22 Years |
| Location | 51 Sockanosset Cross Rd, Cranston, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124095294 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT00674 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pappas Physical Therapy Llc | 2567708233 | 57 |
News Archive
Urologix®, Inc., a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced the selection of two clinical abstracts for podium presentation at the American Urological Association (AUA) 2010 Annual Meeting's sub-specialty society, the Geriatric Urological Society (GUS) meeting.
Pressure BioSciences, Inc. today announced that it has signed a Cooperative Research and Development Agreement ("CRADA") with the Armed Forces Institute of Pathology ("AFIP"), the American Registry of Pathology ("ARP"), and the Department of Veterans Affairs ("VA").
For the first time, researchers have found five regions in the human genome that increase susceptibility to immunoglobulin A nephropathy, a major cause of kidney failure worldwide - systematically identifying those that point to a tendency for IgA nephropathy, or a protection against it.
Ossianix, Inc. today announced a strategic investment by H. Lundbeck A/S in the form of a Convertible Promissory Note. The proceeds from Lundbeck's investment is expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing Ossianix's proprietary single domain antibody platform modeled on the shark vNAR structure.
Researchers from Thomas Jefferson University's Kimmel Cancer Center have discovered that decorin, a naturally occurring protein that circulates in the blood, acts as a potent inhibitor of tumor growth modulating the tumor microenvironment.
› Verified 6 days ago
| Provider Name | Pappas Physical Therapy Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1851862692 PECOS PAC ID: 2567708233 Enrollment ID: O20190117000421 |
News Archive
Urologix®, Inc., a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced the selection of two clinical abstracts for podium presentation at the American Urological Association (AUA) 2010 Annual Meeting's sub-specialty society, the Geriatric Urological Society (GUS) meeting.
Pressure BioSciences, Inc. today announced that it has signed a Cooperative Research and Development Agreement ("CRADA") with the Armed Forces Institute of Pathology ("AFIP"), the American Registry of Pathology ("ARP"), and the Department of Veterans Affairs ("VA").
For the first time, researchers have found five regions in the human genome that increase susceptibility to immunoglobulin A nephropathy, a major cause of kidney failure worldwide - systematically identifying those that point to a tendency for IgA nephropathy, or a protection against it.
Ossianix, Inc. today announced a strategic investment by H. Lundbeck A/S in the form of a Convertible Promissory Note. The proceeds from Lundbeck's investment is expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing Ossianix's proprietary single domain antibody platform modeled on the shark vNAR structure.
Researchers from Thomas Jefferson University's Kimmel Cancer Center have discovered that decorin, a naturally occurring protein that circulates in the blood, acts as a potent inhibitor of tumor growth modulating the tumor microenvironment.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Susan Audrey Parker, DPT 51 Sockanosset Cross Rd, Cranston, RI 02920-5536 Ph: (401) 944-7574 | Mrs Susan Audrey Parker, DPT 51 Sockanosset Cross Rd, Cranston, RI 02920-5536 Ph: (401) 944-7574 |
News Archive
Urologix®, Inc., a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced the selection of two clinical abstracts for podium presentation at the American Urological Association (AUA) 2010 Annual Meeting's sub-specialty society, the Geriatric Urological Society (GUS) meeting.
Pressure BioSciences, Inc. today announced that it has signed a Cooperative Research and Development Agreement ("CRADA") with the Armed Forces Institute of Pathology ("AFIP"), the American Registry of Pathology ("ARP"), and the Department of Veterans Affairs ("VA").
For the first time, researchers have found five regions in the human genome that increase susceptibility to immunoglobulin A nephropathy, a major cause of kidney failure worldwide - systematically identifying those that point to a tendency for IgA nephropathy, or a protection against it.
Ossianix, Inc. today announced a strategic investment by H. Lundbeck A/S in the form of a Convertible Promissory Note. The proceeds from Lundbeck's investment is expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing Ossianix's proprietary single domain antibody platform modeled on the shark vNAR structure.
Researchers from Thomas Jefferson University's Kimmel Cancer Center have discovered that decorin, a naturally occurring protein that circulates in the blood, acts as a potent inhibitor of tumor growth modulating the tumor microenvironment.
› Verified 6 days ago
Robin Lindsey Ness, Physical Therapist Medicare: Medicare Enrolled Practice Location: 721 Reservoir Ave, Cranston, RI 02910 Phone: 401-946-4250 Fax: 401-275-5645 | |
Melany A. Westwell, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1100 Reservoir Ave, Cranston, RI 02910 Phone: 401-785-3334 Fax: 401-785-3336 | |
Megan Elizabeth Miller, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 721 Reservoir Ave, Cranston, RI 02910 Phone: 401-946-4250 Fax: 401-275-5645 | |
Francis Santos Purugganan, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4 Western Hills Ln Apt 2402, Cranston, RI 02921 Phone: 401-767-6704 | |
Randi J Marten, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 721 Reservoir Ave, Cranston, RI 02910 Phone: 401-946-4250 Fax: 401-275-5645 | |
Mrs. Judith Marie Ricci, MSPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 75 Sockanosset Cross Rd, Suite 110, Cranston, RI 02920 Phone: 401-944-7574 Fax: 401-944-7602 | |
Andrew J Going, MSPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 721 Reservoir Ave, Cranston, RI 02910 Phone: 401-946-4250 Fax: 401-275-5645 |